2025
SJR Q2
JCR Q3 · 1,9
OA
14 matched articles
SCIE
Journal detail
Journal of Applied Biomedicine
- Publisher
- University of South Bohemia in Ceske Budejovice Faculty of Health and Social Sciences
- Country
- Czech Republic · Eastern Europe
- Type
- journal
- ISSN
-
1214021X12140287
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,507
- Quartile Q2
- H-Index 42
- Cites/doc 1,96
- Docs (3y) 71
- Cites (3y) 156
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,9
- 5Y JIF 2,1
- JCI 0,48
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Agricultural and Biological Sciences (miscellaneous) Q2
- Artificial Intelligence Q2
- Biochemistry, Genetics and Molecular Biology (miscellaneous) Q2
- Biomedical Engineering Q3
- Health, Toxicology and Mutagenesis Q3
- Immunology and Microbiology (miscellaneous) Q2
- Medicine (miscellaneous) Q3
- Neuroscience (miscellaneous) Q3
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous) Q2
Areas
- Agricultural and Biological Sciences
- Biochemistry, Genetics and Molecular Biology
- Computer Science
- Engineering
- Environmental Science
- Immunology and Microbiology
- Medicine
- Neuroscience
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Medicine, Research & Experimental | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,507 | 1,9 | 2,1 | 0,48 | Q3 | 42 |
| 2024 | Q2 | Q3 | 0,424 | 2 | 1,8 | 0,53 | Q3 | 40 |
| 2023 | Q2 | Q3 | 0,363 | 2 | 1,7 | 0,44 | Q3 | 40 |
| 2022 | Q2 | Q4 | 0,285 | 1,3 | 1,6 | 0,25 | Q4 | 40 |
| 2021 | Q3 | Q4 | 0,246 | 0,5 | 1,6 | 0,37 | Q3 | 40 |
| 2020 | Q2 | Q4 | 0,306 | 1,8 | 1,7 | 0,45 | Q3 | 40 |
| 2019 | Q2 | Q4 | 0,375 | 1,7 | 1,9 | 0,62 | Q3 | 40 |
| 2018 | — | Q4 | — | 1,6 | 1,9 | 0,53 | Q3 | — |
| 2017 | Q2 | Q4 | 0,348 | 1,8 | 1,8 | 0,58 | Q3 | 40 |
| 2016 | Q2 | Q4 | 0,348 | 1,4 | 1,6 | — | — | 40 |
| 2015 | Q2 | Q4 | 0,296 | 1,5 | 1,2 | — | — | 40 |
| 2014 | Q2 | Q3 | 0,247 | 1,3 | 1,4 | — | — | 40 |
| 2013 | Q2 | Q3 | 0,29 | 1,8 | 2 | — | — | 40 |
| 2012 | Q2 | Q4 | 0,324 | 1 | — | — | — | 40 |
| 2011 | Q1 | Q3 | 0,655 | 1,9 | — | — | — | 40 |
| 2010 | Q2 | Q3 | 0,293 | 1,7 | — | — | — | 40 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 129/191 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 253/356 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 125/195 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 232/352 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 122/189 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 222/354 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q4 | 119/136 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 252/278 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 137/139 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 273/279 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 117/140 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 232/276 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 221/271 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 213/267 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 196/261 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 204/257 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 192/255 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 191/255 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 163/256 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 207/261 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 147/261 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 162/252 |